Compare Stocks → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADXNNASDAQ:ATHENASDAQ:DFFNNASDAQ:MTP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$16.10+4.5%$14.43$5.00▼$27.90$17.07M1.6616,770 shs21,438 shsATHEAlterity Therapeutics$2.51+11.1%$1.95$1.55▼$5.41$11.72M0.9477,671 shs87,822 shsDFFNDiffusion Pharmaceuticals$4.64$2.76▼$7.40$8.98M1.7810,937 shs351,000 shsMTPBiodexa Pharmaceuticals$1.95$0.29▼$5.25$6.18M2.2957,354 shs164,300 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-0.90%-26.48%+24.88%+26.10%+2.76%ATHEAlterity Therapeutics-3.00%+5.61%+25.56%+13.57%-19.29%DFFNDiffusion Pharmaceuticals0.00%0.00%0.00%0.00%-22.60%MTPBiodexa Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics0.2201 of 5 stars0.03.00.00.01.70.80.6ATHEAlterity Therapeutics2.5673 of 5 stars3.53.00.00.01.71.71.3DFFNDiffusion PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMTPBiodexa PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics2.00HoldN/AN/AATHEAlterity Therapeutics3.00Buy$7.00178.88% UpsideDFFNDiffusion PharmaceuticalsN/AN/AN/AN/AMTPBiodexa PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest DFFN, ATHE, ADXN, and MTP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/7/2024ATHEAlterity TherapeuticsBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$4.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$1.80M9.48N/AN/A$1.20 per share13.42ATHEAlterity Therapeutics$3.37M3.48N/AN/A$3.78 per share0.66DFFNDiffusion PharmaceuticalsN/AN/AN/AN/A$6.97 per shareN/AMTPBiodexa Pharmaceuticals$800K0.00N/AN/A$5.67 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics-$11.76M-$19.27N/AN/AN/A-653.33%-277.44%-156.74%5/9/2024 (Estimated)ATHEAlterity Therapeutics-$9.30MN/A0.00N/AN/AN/AN/AN/AN/ADFFNDiffusion Pharmaceuticals-$15.59MN/A0.00N/AN/AN/A-69.96%-62.98%N/AMTPBiodexa Pharmaceuticals-$7.51MN/A0.00N/AN/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/AATHEAlterity TherapeuticsN/AN/AN/AN/AN/ADFFNDiffusion PharmaceuticalsN/AN/AN/AN/AN/AMTPBiodexa PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A1.461.46ATHEAlterity TherapeuticsN/A4.89N/ADFFNDiffusion PharmaceuticalsN/A10.7110.71MTPBiodexa PharmaceuticalsN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%ATHEAlterity Therapeutics2.14%DFFNDiffusion Pharmaceuticals9.95%MTPBiodexa Pharmaceuticals4.21%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%ATHEAlterity Therapeutics38.80%DFFNDiffusion Pharmaceuticals1.80%MTPBiodexa Pharmaceuticals0.34%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics241.06 million901,000Not OptionableATHEAlterity Therapeutics114.67 million2.86 millionNot OptionableDFFNDiffusion Pharmaceuticals132.04 million2.00 millionNot OptionableMTPBiodexa Pharmaceuticals1821.67 million21.60 millionNot OptionableDFFN, ATHE, ADXN, and MTP HeadlinesSourceHeadlineExtend Life Expectancy Against Aggressive Brain Cancers - Nano-Cap Firm Biodexa's Investigational Drug Shows Potentialbenzinga.com - March 28 at 1:49 PMWhy Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today?investorplace.com - March 28 at 12:11 PMBiodex stock slides 7% amid data for two drug studiesmsn.com - February 23 at 8:57 PMWhy Is Brain Cancer Focused-Biodexa Pharmaceuticals Stock Trading Higher Today?msn.com - February 13 at 3:11 PMCrude Oil Rises Over 1%; Biodexa Pharmaceuticals Shares Plungemsn.com - December 19 at 4:01 PMBiodexa Announces Pricing of $5.2 Million Underwritten Public Offeringtmcnet.com - December 19 at 9:37 AMBiodexa Pharmaceuticals PLC Announces Results Of Appeal Of Delisting Determinationbenzinga.com - July 8 at 9:54 AMBDRX Biodexa Pharmaceuticals Plcseekingalpha.com - April 25 at 8:04 PMBiodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equityfinance.yahoo.com - April 4 at 3:25 PMWhy Is Midatech Pharma (BDRX) Stock Up 64% Today?investorplace.com - March 28 at 9:17 AMMidatech Pharma PLC Announces Private Placement Raising US $6.0 millionfinance.yahoo.com - February 9 at 3:29 PMBioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plcfinancialpost.com - January 23 at 9:28 AMMidatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Studyfinance.yahoo.com - January 12 at 7:34 AMBIOAF: Merger with Midatech Pharmafinance.yahoo.com - January 3 at 3:29 PMMidatech Pharma PLC Announces Proposed Acquisition of Bioasis Technologies Incfinance.yahoo.com - December 13 at 1:49 PMBioasis Technologies Inc. Announces Merger with Midatech Pharma plcfinance.yahoo.com - December 13 at 1:49 PMMTP Midatech Pharma plcseekingalpha.com - October 11 at 12:50 PMMidatech Pharma Will Need Extra Financing in 1Q 2023; Mulling Optionsmarketwatch.com - September 14 at 10:02 PMMidatech Pharma PLC Announces ADR Ratio Changefinance.yahoo.com - September 14 at 10:17 AMMidatech Pharma PLC Newsthestreet.com - August 3 at 12:44 AMMidatech Pharma PLC Announces MTX110 Development for the Treatment of Gliomafinance.yahoo.com - June 21 at 4:04 AMMidatech Pharma PLC - MTX110 Study to be Presented at ISPNO 2022yahoo.com - June 10 at 3:47 AMMidatech Pharma: MTX110’s Path To Market Fast-Tracked In RGBMuk.investing.com - June 7 at 8:40 PMMidatech Pharma plc [MTP] Revenue clocked in at $0.70 million, down -28.57% YTD: What’s Next?dbtnews.com - June 2 at 6:44 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsCaterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesApril 25, 2024 10:36 AMView Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentYou Can Follow BlackRock’s Market View for Your MoneyApril 12, 2024 10:00 AMView You Can Follow BlackRock’s Market View for Your MoneyAll Headlines Company DescriptionsAddex TherapeuticsNASDAQ:ADXNAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Alterity TherapeuticsNASDAQ:ATHEAlterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Diffusion PharmaceuticalsNASDAQ:DFFNDiffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.Biodexa PharmaceuticalsNASDAQ:MTPBiodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.